Growth funding Forbion manages just over €5 billion across multiple fund strategies and actively invests across all stages of (bio-) pharmaceutical drug development, indicating ongoing fundraising and capacity for additional co-investments or fund-for-fund opportunities.

BioEconomy focus The firm operates a BioEconomy fund strategy targeting sustainable solutions beyond human health, presenting sales potential for portfolio companies or service providers in food, agriculture, materials, and environmental technologies.

Planetary health leadership Joy Faucher’s role as General Partner to lead planetary health initiatives signals a strategic emphasis that could drive partnership conversations around sustainability, impact investing, and cross-portfolio collaborations.

Strategic acquisitions Forbion European Acquisition Corp has been actively investing in seed to Series A rounds for biotech and biomaterials ventures (e.g., Seamless Therapeutics, LoQus23, Pact, EEDEN), suggesting receptivity to co-investments, deal sourcing partnerships, and advisory services.

Operational scale With a global footprint in Europe, a midsize employee base, and notable funding milestones (e.g., €200M BioEconomy Fund I), there is opportunity to offer specialized technology, data, and portfolio management solutions aligned with their fund and portfolio companies.